MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a waiver

MHRA-100330-PIP01-21

Scope of the Application

Active Substance(s)

Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LVV, encoding for the human #-L-iduronidase (IDUA) gene (OTL-203)

Condition(s)

Treatment of Mucopolysaccharidosis type I, Hurler syndrome (MPS-IH)

Pharmaceutical Form(s)

Dispersion for infusion

Route(s) of Administration

Intravenous use

Name / Corporate name of the PIP applicant

Orchard Therapeutics (Europe) Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Orchard Therapeutics (Europe) Ltd submitted to the licensing authority on 17/12/2021 16:29 GMT an application for a Paediatric Investigation Plan

The procedure started on 11/05/2022 10:11 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100330-PIP01-21

Of 13/05/2022 13:18 BST

On the adopted decision for Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LVV, encoding for the human #-L-iduronidase (IDUA) gene (OTL-203) (MHRA-100330-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LVV, encoding for the human #-L-iduronidase (IDUA) gene (OTL-203), Dispersion for infusion , Intravenous use .

This decision is addressed to Orchard Therapeutics (Europe) Ltd, 108 Cannon Street, London, United Kingdom, EC4N 6EU

ANNEX I

1. Waiver

1.1 Condition:

Treatment of Mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 28 days of age Pharmaceutical form(s): Dispersion for infusion Route(s) of administration: Intravenous use Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of Mucopolysaccharidosis type I, Hurler syndrome (MPS-IH)

2.2 Indication(s) targeted by the PIP:

Treatment of Mucopolysaccharidosis type I, Hurler syndrome (MPS-IH)

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 28 days to less than 18 years of age

2.4 Pharmaceutical Form(s):

Dispersion for infusion

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable
Non-Clinical Studies	0	Not applicable
Clinical Studies	2	Study 1 (TigetT10_MPSIH) Non-randomised, open-label study to evaluate safety and efficacy of OTL-203 for the treatment of patients from 28 days of age affected by mucopolysaccharidosis Type I, Hurler syndrome (MPS-IH). Study 2 (OTL-203-02) Multicentre, non-randomised, clinical trial comprising an open-label, prospective study to evaluate the efficacy and safety of OTL-203 in subjects affected with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) [Part A], and a contemporaneous data collection of clinical outcomes in MPS-IH subjects referred for treatment with allogeneic haematopoietic stem cell transplant (allo-HSCT) [Part B].
Extrapolation, Modeling & Simulation Studies	0	Not applicable
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/03/2027

Deferral of one or more studies contained in the paediatric investigation plan:	No